What is the official website of Pharmaceutical Commerce ?

The official website of Pharmaceutical Commerce is http://PharmaceuticalCommerce.com.

What is Pharmaceutical Commerce's cybersecurity risk score?

Pharmaceutical Commerce has an AI-generated cybersecurity risk score of 751 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Pharmaceutical Commerce experienced?

According to Rankiteo, Pharmaceutical Commerce currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Pharmaceutical Commerce been affected by any supply chain cyber incidents ?

According to Rankiteo, Pharmaceutical Commerce has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Pharmaceutical Commerce have SOC 2 Type 1 certification ?

According to Rankiteo, Pharmaceutical Commerce is not certified under SOC 2 Type 1.

Does Pharmaceutical Commerce have SOC 2 Type 2 certification ?

According to Rankiteo, Pharmaceutical Commerce does not hold a SOC 2 Type 2 certification.

Does Pharmaceutical Commerce comply with GDPR ?

According to Rankiteo, Pharmaceutical Commerce is not listed as GDPR compliant.

Does Pharmaceutical Commerce have PCI DSS certification ?

According to Rankiteo, Pharmaceutical Commerce does not currently maintain PCI DSS compliance.

Does Pharmaceutical Commerce comply with HIPAA ?

According to Rankiteo, Pharmaceutical Commerce is not compliant with HIPAA regulations.

Does Pharmaceutical Commerce have ISO 27001 certification ?

According to Rankiteo,Pharmaceutical Commerce is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Pharmaceutical Commerce operate in ?

Pharmaceutical Commerce operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Pharmaceutical Commerce have ?

Pharmaceutical Commerce employs approximately 32 people worldwide.

Does Pharmaceutical Commerce own any subsidiaries ?

Pharmaceutical Commerce presently has no subsidiaries across any sectors.

How many LinkedIn followers does Pharmaceutical Commerce have ?

Pharmaceutical Commerce's official LinkedIn profile has approximately 8,078 followers.

What is the NAICS classification code for Pharmaceutical Commerce ?

Pharmaceutical Commerce is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Pharmaceutical Commerce have a Crunchbase profile ?

No, Pharmaceutical Commerce does not have a profile on Crunchbase.

Does Pharmaceutical Commerce have a LinkedIn profile ?

Yes, Pharmaceutical Commerce maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/pharmaceutical-commerce.

How many cybersecurity incidents has Pharmaceutical Commerce experienced ?

As of September 3, 2026, Rankiteo reports that Pharmaceutical Commerce has not experienced any cybersecurity incidents.

How many peer or competitor companies does Pharmaceutical Commerce have ?

Pharmaceutical Commerce has an estimated 5,751 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Pharmaceutical Commerce

Boost Score +25 with badge (5 left)

751

/1000

Fair

776

/1000

Fair

Pharmaceutical Commerce Vendor Cyber Rating & Cyber Score

PharmaceuticalCommerce.com

Add Your Compliance Badge

Pharmaceutical Commerce is dedicated to the commercial operations of the North American pharmaceutical industry. Four times a year, its 16,000 executive readers get the latest information and analysis commercial operations, marketing/sales best practices, supply chain management, product packaging and security, information technology and legal/regulatory services. The magazine covers the flow of products into distribution channels, the flow of information between the industry and healthcare providers, and the flow of funds in trading and payer agreements.

Pharmaceutical Commerce A.I CyberSecurity Scoring

Scoring History

Pharmaceutical Commerce

Pharmaceutical Commerce CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Pharmaceutical Commerce Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Pharmaceutical Commerce

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Pharmaceutical Commerce in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Pharmaceutical Commerce in 2026.

Incident Types Pharmaceutical Commerce vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Pharmaceutical Commerce in 2026.

Incident History - Pharmaceutical Commerce (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Pharmaceutical Commerce Subsidiaries

Parent Company

Pharmaceutical Commerce

Pharmaceutical Manufacturing

Website: http://PharmaceuticalCommerce.com

Company Size: 32

No subsidiary data available for this company.

Loading…

Pharmaceutical Commerce Similar Companies

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Novartis

novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Loading…

NEWS

Pharmaceutical Commerce CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 02, 2026 08:19 PM

Pharma Pulse: Regulatory Speed Records

In today's Pharma Pulse, the FDA grants a lightning-fast approval for Boehringer's lung cancer therapy under its new priority program,...

Read Article

February 27, 2026 10:03 PM

Cybersecurity and AI in the Era of Home-Based Care Logistics

A conversation with Kenco's Tim McClatchy explores how pharmaceutical logistics providers are strengthening cybersecurity across...

Read Article

February 27, 2026 09:35 PM

Quality and Compliance in the Pharmaceutical Industry: Navigating a Transformed Landscape

Rising recalls, tighter FDA enforcement, global supply chain dependencies, and rapid technology shifts are reshaping pharmaceutical quality...

Read Article

February 26, 2026 03:19 PM

Flat 2027 Medicare Advantage Rates Signal Tighter Budgets—and Tougher Access Ahead

CMS's CY 2027 Medicare Advantage rates signal mounting cost pressure, setting the stage for tighter benefits, tougher contracting,...

Read Article

February 10, 2026 08:00 AM

FAQ: What Domestic Manufacturing Means for Drug Supply Chains

As policy pressure, tariffs, and supply chain risks push drugmakers to expand US-based production, this FAQ explains what pharma reshoring...

Read Article

January 16, 2026 08:00 AM

Article | This pharmaceutical executive has Trump's ear

Corporate CEOs trying to figure out how to get on President Donald Trump's good side need look no further. David Ricks, CEO of the...

Read Article

January 09, 2026 01:07 PM

How AI Is Transforming Healthcare and Pharma

Philip Sclafani, PwC's pharmaceutical and life sciences lead, provides a breakdown of how AI is disrupting the healthcare industry, moving past the...

Read Article

January 02, 2026 08:00 AM

Modernizing the Last Mile

In the final part of his Pharma Commerce video interview, Arthur Axelrad, co-founder and CEO of Dispatch Science, explains how outdated,...

Read Article

December 23, 2025 08:00 AM

Trade & Channel Strategies 2025: Why Wholesalers Remain Pharma’s Backbone

As drugmakers experiment with direct-to-patient sales, Thani Jambulingam, PhD, professor of food, pharma, and healthcare business at Saint...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-84857

SUMMARY

A flaw has been found in sigoden aichat up to 0.30.4. This affects an unknown function of the file src/serve.rs of the component API Endpoint. This manipulation causes uncontrolled memory allocation. The attack can be initiated remotely. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-02

Updated

Date2026-09-02

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:N/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-84856

SUMMARY

A vulnerability was detected in rowboatlabs rowboat up to 0.9.1. The impacted element is the function request.text/req.json of the file apps/rowboat/app/api/composio/webhook/route.ts of the component Composio Webhook Endpoint. The manipulation results in denial of service. It is possible to launch the attack remotely. The exploit is now public and may be used. Upgrading to version 0.9.2 is sufficient to resolve this issue. Upgrading the affected component is recommended. The legacy Next.js app was deleted at 0.9.2 rather than patched, leaving no security control behind.

Published

Date2026-09-02

Updated

Date2026-09-02

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:N/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-84852

SUMMARY

A security vulnerability has been detected in Reader Tools PDF Reader App 98.8 on Android. The affected element is the function ActSplashNew.handleDeeplink of the component File Handler. The manipulation of the argument _display_name leads to path traversal. An attack has to be approached locally. The exploit has been disclosed publicly and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-02

Updated

Date2026-09-02

RISK INFORMATION (Score: 4.4)

cvss2

Base Score: 3.2

Complexity: LOW

AV:L/AC:L/Au:S/C:N/I:P/A:P

cvss3

Base Score: 4.4

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:L

cvss4

Base Score: 1.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:N/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

1.8

REFERENCES

CVE-2026-84452

SUMMARY

Windows ML CLI is a command line tool for building portable, performant, and high-quality AI models for Windows ML. Prior to 0.4.0, the src/winml/modelkit/serve/cli_api.py component exposes WinML CLI commands through a localhost HTTP API without authentication and configures the allow_origins setting as a wildcard in both src/winml/modelkit/serve/cli_api.py and src/winml/modelkit/serve/app.py. A malicious website loaded by a user can send cross-origin requests to /v1/cli/build or /v1/cli/config and set the trust_remote_code parameter to true, which is converted to the --trust-remote-code command-line flag without validation. This reaches AutoConfig.from_pretrained with trust_remote_code=True in src/winml/modelkit/loader/_autoconfig.py and imports Python code from an attacker-controlled model repository, resulting in arbitrary code execution as the server user. This issue is fixed in version 0.4.0.

Published

Date2026-09-02

Updated

Date2026-09-02

RISK INFORMATION (Score: )

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-84292

SUMMARY

fast-uri serializes the port component of a URI without validating it. When recomposing the authority, the userinfo and host components are escaped but the port is concatenated verbatim, so a port value that is not a sequence of digits can inject authority delimiters, demoting the intended host to userinfo and pointing the authority at an attacker-controlled host. Both fast-uri and Node's URL read the result back as the attacker's host with no error, so re-validating the built URI does not catch it. This affects applications that build URIs from parts and assign untrusted data to the port component through the serialize, normalize, or equal functions in their object forms. The issue affects fast-uri versions before 2.4.6, from 3.0.0 before 3.1.7, and from 4.0.0 before 4.1.4. It is fixed in 2.4.6, 3.1.7, and 4.1.4, where recomposeAuthority rejects any port that is not a digit sequence per RFC 3986.

Published

Date2026-09-02

Updated

Date2026-09-02

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…